10527097

to a collection of information unless it contains a valid OMB control number. Application Number

	Filing Date		2005-03-09		
	First Named Inventor		Smola		
STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Art Unit		1617		
(Hot for outsinosion ander or or it many	Examiner Name	Unkn	own		
	Attorney Docket Numb	er	0112701-598		

				U.	S.PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
	1	5656588		1997-08-12	Zaloga et al.					
	2	6365175		2002-04-02	Alaiuf et al.					
If you wisi	h to a	dd additional U.S. Pate	nt citatio	n information	please click the	e Add button.		Add		
			U.S.P	ATENT APP	LICATION PUB	BLICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date			Releva		Lines where les or Releva	
	1	20010043983		2001-11-22	Hamilton					
	2	20020041890		2002-04-11	Steven et al.					
	3									
If you wisi	h to a	dd additional U.S. Publ	ished Ap		tion information		d button	Add		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	y Kin	T	Name of Patente Applicant of cited Document	e or	Pages,Coli where Rela	or Relevant	

INFORMATION DISCLOSURE			Application Number Filing Date				10527097 2005-03-09			
			First Named Inventor Smola			Smol	nola			
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Art Unit  Examiner Name Unknown				1617 known				
					Unkn					
			Attorney Docket Number			er	0112701-598			
			T							

1	WO 98/00024	wo		1998-01-08		
2	0 845 266	EP	A	1998-06-03		
3	WO 02/11745	wo	A	2002-02-14		
4	WO 02/47655	wo	A	2002-06-20		
5	WO 01/185127	wo	A	2001-11-15		
6	1427387	EP	A	2004-06-16		
7	2808682	FR	A	2001-11-16		
8	10108097	DE	A	2001-09-13		
9	2 818 136	FR		2002-06-21		
10	0 761 214	EP		1997-03-12		
11	1230952	EP		2002-08-14		

# | Application Number | 10527097 | Filing Date | 2005-03-09 | Filing Date |

If you wisl	h to a	additional Foreign Patent Document citat	tion information please click the Add button	Add	
		NON-PATENT L	ITERATURE DOCUMENTS	Remove	
Examiner Initials*	Cite No		ETTERS), title of the article (when appropria m, catalog, etc), date, pages(s), volume-issu hed.		Тs
	1		ism in A Dermal And Skin Equivalent Model: A S Cosmetic Science, Blackwell Scientific Publication P001128165, ISSN: 0142-5463.		
	2				
If you wis	h to a	additional non-patent literature documen	t citation information please click the Add bu	itton Add	_
		EXAMI	NER SIGNATURE		
Examiner	Signa	ıre	Date Considered		
			citation is in conformance with MPEP 609.		

See Kind Codes of USPTO Plantin Documents at year, USPTO\_EDIZ or MEPP 911.04. \* Enter office and assess the document, by the to-electrood (WIPO Standard ST.3.). \*\*Explainase plants documents, the reduction or the year of the region of the Enterer must proceed the senial number of the plants document. \*
\*\*India of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*\*Applicant is to place a check mark here if training interpretables in statistical.\*\*

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number Filing Date		10527097
			2005-03-09
	First Named Inventor	Smol	la
	Art Unit		1617
	Examiner Name	Unkn	IOWTI
Attorney Docket Number		er	0112701-598

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication of forms a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(a)(1).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inequiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
  - □ None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Robert M. Barrett/	Date (YYYY-MM-DD)	2006-07-14
Name/Drint	Robort M. Barrett	Registration Number	30 142

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandriu, V.S. 2213.1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.